Early Disease-Modifying Treatments for Presymptomatic Multiple Sclerosis

被引:0
|
作者
Zeydan, Burcu [1 ,2 ]
Azevedo, Christina J. [3 ]
Makhani, Naila [4 ,5 ]
Cohen, Mikael [6 ]
Tutuncu, Melih [7 ]
Thouvenot, Eric [8 ,9 ]
Siva, Aksel [7 ]
Okuda, Darin T. [10 ,11 ]
Kantarci, Orhun H. [2 ]
Lebrun-Frenay, Christine [6 ]
机构
[1] Mayo Clin, Dept Radiol, 200 First St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA
[3] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA
[4] Yale Sch Med, Dept Pediat, New Haven, CT USA
[5] Yale Sch Med, Dept Neurol, New Haven, CT USA
[6] Cote Azur Univ, Pasteur 2 Univ Hosp, Dept Neurol, MS Clin Nice,UR2CA URRIS, Nice, France
[7] Istanbul Univ, Cerrahpasa Sch Med, Dept Neurol, Istanbul, Turkiye
[8] Univ Montpellier, Nimes Univ Hosp Ctr, Dept Neurol, Nimes, France
[9] Montpellier Univ, IGF, CNRS, INSERM, Montpellier, France
[10] Univ Texas Southwestern Med Ctr, Neuroinnovat Program, Dallas, TX USA
[11] Univ Texas Southwestern Med Ctr, Multiple Sclerosis & Neuroimmunol Imaging Program, Dallas, TX USA
基金
美国国家卫生研究院;
关键词
RADIOLOGICALLY ISOLATED SYNDROME; INTRAMUSCULAR INTERFERON BETA-1A; 1ST DEMYELINATING EVENT; CLINICALLY DEFINITE; FOLLOW-UP; CONVERSION; ASSOCIATION; DIAGNOSIS; REVISIONS; PHASE;
D O I
10.1007/s40263-024-01117-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Radiologically isolated syndrome (RIS) is the earliest stage in the disease continuum of multiple sclerosis (MS). RIS is discovered incidentally in individuals who are asymptomatic but have typical lesions in the brain and/or spinal cord suggestive of demyelination. The 2009 and revised 2023 RIS criteria were developed for diagnosis. Presymptomatic individuals who fulfill the 2009 RIS criteria by having 3-4 of 4 dissemination in space McDonald 2005 MS criteria are still diagnosed with RIS using the revised 2023 RIS criteria. In presymptomatic individuals who do not fulfill the 2009 RIS criteria, the revised 2023 RIS criteria target to secure an accurate and timely diagnosis: In addition to (a) having one lesion in two of four locations (periventricular, juxtacortical/cortical, infratentorial, spinal cord), (b) two of three features (spinal cord lesion, cerebrospinal fluid (CSF)-restricted oligoclonal bands, and new T2 or gadolinium-enhancing lesion) should be fulfilled. Among laboratory biomarkers, CSF kappa-free light chain can also increase diagnostic accuracy. Once the diagnosis is confirmed, the established risk factors, including demographics, imaging, and laboratory biomarkers, should be evaluated for symptomatic MS transition and prognosis. Younger age, male sex, increased neurofilament-light chain, CSF abnormality, and the presence of infratentorial, spinal cord, or gadolinium-enhancing lesions on imaging are the main risk factors for transition to symptomatic MS. Two randomized clinical trials showed significant efficacy of disease-modifying treatments in delaying or preventing the development of the first clinical event in RIS. However, because some individuals remain as RIS, it is crucial to identify the individuals with a higher number of risk factors to optimize disease outcomes by early intervention while minimizing adverse events. Discussing each RIS case with an expert MS team is recommended because there is still a lack of clinical guidelines to improve care, counseling, and surveillance.
引用
收藏
页码:973 / 983
页数:11
相关论文
共 50 条
  • [41] Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations
    Brownlee, Wallace J.
    Wolf, Christian
    Hartung, Hans-Peter
    Dingermann, Theo
    Anshasi, Nadia
    Clark, Richard A. C.
    Trojano, Maria
    Selmaj, Krzysztof
    Uitdehaag, Bernard M. J.
    Tur, Carmen
    Wuerfel, Jens
    Dallmann, Gabriele
    Witte, Julian
    Sintzel, Martina
    Bobrovnikova, Olga
    Cohen, Jeffrey A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (14) : 2177 - 2189
  • [42] How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP)
    Bigaut, Kevin
    Cohen, Mikael
    Durand-Dubief, Francoise
    Maillart, Elisabeth
    Planque, Evelyne
    Zephir, Helene
    Lebrun-Frenay, Christine
    de Seze, Jerome
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 53
  • [43] Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management
    Oreja-Guevara, Celia
    Martinez-Yelamos, Sergio
    Eichau, Sara
    Llaneza, Miguel Angel
    Martin-Martinez, Jesus
    Pena-Martinez, Joaquin
    Meca-Lallana, Virginia
    Alonso-Torres, Ana Maria
    Moral-Torres, Ester
    Rio, Jordi
    Calles, Carmen
    Ares-Luque, Adrian
    Ramio-Torrenta, Lluis
    Marzo-Sola, Maria Eugenia
    Prieto, Jose Maria
    Martinez-Gines, Maria Luisa
    Arroyo, Rafael
    Otano-Martinez, Maria Angeles
    Brieva-Ruiz, Luis
    Gomez-Gutierrez, Montserrat
    Rodriguez-Antiguedad, Alfredo
    Sanchez-Seco, Victoria Galan
    Costa-Frossard, Lucienne
    Hernandez-Perez, Miguel Angel
    Landete-Pascual, Lamberto
    Gonzalez-Platas, Montserrat
    Meca-Lallana, Jose E.
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2024, 17
  • [44] Cost of disease-modifying therapies for multiple sclerosis
    Brown, Murray G.
    NEUROLOGY, 2015, 84 (21) : E181 - E185
  • [45] Emerging multiple sclerosis disease-modifying therapies
    Giacomini, Paul S.
    Darlington, Peter J.
    Bar-Or, Amit
    CURRENT OPINION IN NEUROLOGY, 2009, 22 (03) : 226 - 232
  • [46] DISEASE-MODIFYING THERAPIES FOR MULTIPLE-SCLEROSIS
    CARTER, JL
    CNS DRUGS, 1995, 3 (02) : 99 - 114
  • [47] Emerging Disease-Modifying Therapies in Multiple Sclerosis
    Perumal, Jai
    Khan, Omar
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2012, 14 (03) : 256 - 263
  • [48] Multiple sclerosis disease-modifying therapy and pregnancy
    Miller, Aaron E.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : 715 - 716
  • [49] Discontinuing disease-modifying multiple sclerosis therapies
    Krysko, Kristen
    LANCET NEUROLOGY, 2023, 22 (07): : 543 - 545
  • [50] Update on disease-modifying therapies for multiple sclerosis
    Vargas, Diana L.
    Tyor, William R.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2017, 65 (05) : 883 - 891